<DOC>
	<DOCNO>NCT02098824</DOCNO>
	<brief_summary>Single center threeway double blind cross trial investigate pharmacological responsivity patient VCI use challenge aim monoaminergic cholinergic neuronal system</brief_summary>
	<brief_title>Symptomatic Treatment Vascular Cognitive Impairment</brief_title>
	<detailed_description>Vascular Cognitive Impairment important cause cognitive impairment dementia . Till , approve symptomatic treatment Vascular Cognitive Impairment . Research novel pharmacological treatment may reduce clinical symptom patient need . Evidence suggest executive dysfunction memory impairment Vascular Cognitive Impairment cause damage monoaminergic cholinergic neurotransmitter-systems , respectively . However , patient Vascular Cognitive Impairment form clinically heterogeneous group , i.e . extent executive function memory affect differs patient patient . Previous intervention study take inter-patient variability account . Individually tailored pharmacological intervention , aim affected neurotransmitter system , may ameliorate cognitive symptom patient Vascular Cognitive Impairment . Using pharmacological challenge , possible detect individual sensitivity specific pharmacological intervention . Furthermore , use novel MRI technique , possible correlate location severity cerebrovascular lesion impaired structural functional connectivity subject . The investigator recruit 30 patient Vascular Cognitive Impairment ( accord criterion American Heart Association/American Stroke Association ) , Alzheimer Center VU University Medical Center Utrecht University Medical Center . They also undergo MRI , include diffusion tensor image MRI ( DTI ) /'fiber track ' ; rest state ( RS ) functional MRI ( fMRI ) . In double-blind , three-way , case cross trial , investigator study effect methylphenidate executive function galantamine episodic memory function . During three separate visit , patient receive pharmacological intervention ( placebo , methylphenidate , galantamine ) investigator Clinical Research Unit . Also , study day investigator collect blood sample different timepoints .</detailed_description>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Dementia , Vascular</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Outpatients Objective executive dysfunction and/or memory impairment neuropsychological test image evidence cerebrovascular disease ( white matter change ( Fazekas ≥2 , ( lacunar ) infarcts ) Mini Mental State Examination ( MMSE ) ≥16 Clinical Dementia Rating Score ( CDR 0.51 ) No contraindication treatment Cholinesterase inhibitor ( CEI ) Methylphenidate ( MPH ) ( www.fk.cvz.nl ) Assessed treat neurologist mentally capable understanding implication study participation Presence informant/caregiver information visit , sign informed consent , study visit Clinically relevant history abnormal physical mental health interfere study determine medical history take physical examination obtain screen visit and/or study day judge investigator ; Clinically relevant abnormal laboratory result , electrocardiogram ( ECG ) vital sign , physical finding screen and/or start study day ( judged investigator ) ; Unwilling unable stop smoking study day end study day Other cause explain cognitive symptom include limited : delirium , multiple sclerosis , amyotrophic lateral sclerosis , progressive supranuclear palsy , mental retardation , infectious encephalitis lead persistent cognitive deficit head trauma loss consciousness lead persistent cognitive deficit Use neuroleptic Use celiprolol sotalol Use MAOA/B inhibitor Current use centrally act anticholinergic ( e.g . oxybutynin , mebeverine , ipratropium ( bromide ) ) Use benzodiazepine within 48 hour study day Current use CEI ( rivastigmine , galantamine , donepezil ) Alcohol abuse ( define use alcohol despite significant area dysfunction , evidence physical dependence , and/or related hardship due alcohol ) Use recreational drug Concomitant use inhibitor CYP2D6 ( a/o kinidine , paroxetine , fluoxetine ) CYP3A4 ( a/o ketoconazole , ritonavir ) ; unless patient stable dose without recent upcoming change Any condition opinion investigator would complicate compromise study , well subject . Any contraindication MRI</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>vascular cognitive impairment</keyword>
	<keyword>treatment</keyword>
	<keyword>cerebrovascular lesion</keyword>
	<keyword>memory impairment</keyword>
	<keyword>executive dysfunction</keyword>
	<keyword>neuronal network</keyword>
	<keyword>white matter tract</keyword>
	<keyword>monoaminergic system</keyword>
	<keyword>cholinergic system</keyword>
	<keyword>DTI</keyword>
	<keyword>rs-fMRI</keyword>
</DOC>